Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Muscle weakness linked to worse outcomes in lung disease patients

NCT ID NCT07178197

Knowledge-focused Sponsor: Mersin University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study looked at 60 people with idiopathic pulmonary fibrosis (IPF) to see how common muscle loss (sarcopenia) is and how it affects their quality of life and disease progression. Researchers measured muscle strength, walking speed, lung function, and used a questionnaire to assess quality of life. The goal was to better understand the role of sarcopenia in IPF, which has not been well studied.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the findings show a clear link, it could help doctors identify which IPF patients need extra support to maintain muscle strength and quality of life.
What could go wrong
This is a small, observational study that only looks at one point in time. It cannot prove cause and effect, and results may not apply to all IPF patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

60 people

The number who actually took part.

Started

Dec 2022

Finished

Dec 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients included in the study were those diagnosed with IPF according to the ATS/ERS/JRS/ALAT 2022 guidelines and who applied to the Department of Pulmonary Diseases at Mersin University Faculty of Medicine.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Being over 18 years of age * Signing the informed consent form * Having a diagnosis of IPF for at least one month Exclusion Criteria: * Pregnancy * History of cancer within the last 5 years * History of lung surgery * History of neuromuscular disease * Active pulmonary tuberculosis * Active respiratory tract infection * Inability to perform pulmonary function tests * Presence of a pacemaker * History of systemic steroid use within the past 3 months * Inability to use a hand dynamometer

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Idiopathic pulmonary fibrosis (IPF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Idiopathic pulmonary fibrosis (IPF) Sarcopenia

Contacts and locations

Locations

  • Mersin University Faculty of Medicine

    Mersin, Mersin, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.